USITC Commissioner Series: Top Dissenting Issues
April 22, 2024, 8:36 AM
This is part three of our USITC Commissioner Series.
Read part one here, part two here, part four here and part five here.
Following my colleagues’ efforts in this series, this post examines the dissent/concurrence practice of the Commissioners at the U.S. International Trade Commission (USITC) – specifically the “hot” issues that drew the most dissents in the past 10 years.
In terms of broad categories, the data our team gathered (visualized below) shows that issues relating to remedial orders drew the vast majority (61%) of the dissents/concurrences, followed distantly by the economic prong of the domestic industry (DI) requirement (24%). Patent merits issues (e.g., patent infringement, invalidity, and the technical prong of DI) made up only 12% of the dissents/concurrences, with the remaining 4% evenly split between importation issues and procedural issues.

Most-Dissented Remedial Order Issues
Within the dissents/concurrences on remedial order issues, about 60% relate to the proper standards for issuing cease-and-desist orders (CDOs). As my colleagues previously analyzed, Commissioner Schmidtlein has been the leading dissenter in this area, especially with respect to whether a respondent’s domestic inventory of infringing articles must be “commercially significant” in order to issue a CDO. The question of whether repair or replacement exemptions should be granted for components of infringing articles was also the subject of a considerable amount (13%) of dissents/concurrences.

Most-Dissented DI Economic Prong Issues
With respect to DI economic prong issues, the top dissented issue was the “significance” of qualifying investment/expenditures, making up 37% of the dissents/concurrences on economic DI issues. As my colleagues noted, Commissioner Kearns has been leading the charge on this issue. Other top economic DI issues drawing dissents/concurrences include questions on what types of investments/expenditures qualify for DI considerations (22%) and whether a complainant’s activities are different from those of a “mere importer” (17%).


To subscribe to our publications, click here.
News & Insights
News & Insights
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2025
Sponsorship
Antitrust
ACI 21st Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
ABA 73rd Annual Section of Antitrust Law Spring Meeting
Speaking Engagement
Antitrust
AIPLA CLE Web Series: Hot Topics in Chemical & Biotech Patent Practice
Speaking Engagement
17th Annual Practitioners' Think Tank on ITC Litigation & Enforcement
Speaking Engagement
Intellectual Property
Antitrust Enforcement Trends and Policies in 2025: Unfair Competition, Merger Policies, Premerger Procedures
Webinar
Antitrust
CompLaw Nordic 2025
Speaking Engagement
Antitrust
Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights
Axinn Viewpoints
Intellectual Property